Transcripts containing a small anti-HIV hammerhead ribozyme that are active in the cell cytoplasm but inactive in vitro as free RNAs

Biochimie

Volumn 78, Issue 7, 1996, Pages 654-662

  Domi, A ^a   Beaud, G ^a   Favre, A ^a  

^a INSTITUT JACQUES MONOD   (France)

Author keywords

Catalytic RNA; Hammerhead ribozyme; HIV; Vaccinia virus

Indexed keywords

COMPLEMENTARY RNA; RIBOZYME;

ARTICLE; CYTOPLASM; ENZYME ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA METABOLISM; RNA STRUCTURE; VACCINIA VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA; VACCINIA VIRUS;

EID: 0029963514     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(96)80011-3     Document Type: Article

References (54)

1. Prody GA, Bakos JT, Buzayan JM, Schneider IR, Bruening G. Autolytic processing of dimeric plant virus satellite RNA. Science. 232:1986;1577-1580.
2. Forster AC, Symons RH. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell. 49:1987;211-220.
3. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature (Lond). 328:1987;596-600.
4. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (Lond). 334:1988;585-591.
5. Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry. 29:1990;10695-10702.
6. Sheldon CC, Symons RH. Mutagenesis analysis of self-cleaving RNA. Nucleic Acids Res. 17:1989;5679-5685.
7. Tabler M, Homann M, Tzortzakaki S, Sczakiel G. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design. Nucleic Acids Res. 22:1994;3958-3965.
8. Zoumadakis M, Tabler M. Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes. Nucleic Acids Res. 23:1995;1192-1196.
9. Cotten M, Birnstiel ML. Ribozyme mediated destruction of RNA in vivo. EMBO J. 8:1989;3861-3866.
10. Cameron FH, Jennings PA. Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci USA. 86:1989;9139-9143.
11. Saxena SK, Ackerman EJ. Ribozymes correctly cleave a model substrate and endogenous RNA in vivo. J Biol Chem. 265:1990;17106-17109.
12. Dropulic B, Lin NH, Martin MA, Jeang KT. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J Virol. 66:1992;1432-1441.
13. L'Huillier PJ, Davis SR, Bellamy AR. Cytoplasmic delivery of ribozymes leads to efficient reduction in alpha-lactalbumin mRNA levels in C127I mouse cells. EMBO J. 11:1992;4411-4418.
14. Steinecke P, Herget T, Schreier PH. Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo. EMBO J. 11:1992;1525-1530.
15. Ellis J, Rogers J. Design and specificity of hammerhead ribozymes against calretinin mRNA. Nucleic Acids Res. 21:1993;5171-5178.
16. Bertrand E, Pictet R, Grange T. Can hammerhead ribozymes be efficient tools to inactivate gene function? (published erratum appeared in Nucleic Acids Res, 1994, 22, 1326) Nucleic Acids Res. 22:1994;293-300.
17. Bertrand EL, Rossi JJ. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J. 13:1994;2904-2912.
18. Denman RB, Smedman M, Ju W, Rubenstein R, Potempska A, Miller DL. Ribozyme mediated degradation of beta-amyloid peptide precursor mRNA in COS-7 cells. Nucleic Acids Res. 22:1994;2375-2382.
19. Larsson S, Hotchkiss G, Andang M, Nyholm T, Inzunza J, Jansson I, Ahrlund RL. Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res. 22:1994;2242-2248.
20. Steinecke P, Steger G, Schreier PH. A stable hammerhead structure is not required for endonucleolytic activity of a ribozyme in vivo. Gene. 149:1994;47-54.
21. Scanlon KJ, Ishida H, Kashani SM. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci USA. 91:1994;11123-11127.
22. Mahieu M, Deschuyteneer R, Forget D, Vandenbussche P, Content J. Construction of a ribozyme directed against human interleukin-6 mRNA: evaluation of its catalytic activity in vitro and in vivo. Blood. 84:1994;3758-3765.
23. Kiehntopf M, Esquivel EL, Brach MA, Herrmann F. Ribozymes: biology, biochemistry, and implications for clinical medicine. J Mol Med. 73:1995;65-71.
24. Rossi JJ. Making ribozymes work in cells. Curr Biol. 4:1994;471.
25. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ. Ribozymes as potential anti-HIV-1 therapeutic agents. Science. 247:1990;1222-1225.
26. Weerashinghe M, Liem SE, Asad S, Read SE, Joshi S. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retro-viral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol. 65:1991;5531-5534.
27. Sioud M, Drlica K. Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc Natl Acad Sci USA. 88:1991;7303-7307.
28. Chen CJ, Banerjea AC, Harmison GG, Haglund K, Schubert M. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication - potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20:1992;4581-4589.
29. Lo KM, Biasolo MA, Dehni G, Palu G, Haseltine WA. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology. 190:1992;176-183.
30. Rossi JJ, Sarver N. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents. Adv Exp Med Biol. 312:1992;95-109.
31. Goodchild J. Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2'-O-methylation. Nucleic Acids Res. 20:1992;4607-4612.
32. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci USA. 88:1991;6921-6925.
33. Ojwang JO, Hampel A, Looney DJ, Wong SF, Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hair-pin ribozyme. Proc Natl Acad Sci USA. 89:1992;10802-10806.
34. Sullenger BA, Cech TR. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science. 262:1993;1566-1569.
35. Homann M, Tzortzakaki S, Rittner K, Sczakiel G, Tabler M. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Res. 21:1993;2809-2814.
36. Sun LQ, Warrilow D, Wang L, Witherington C, Macpherson J, Symonds G. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Proc Natl Acad Sci USA. 91:1994;9715-9719.
37. Yuyama N, Ohkawa J, Koguma T, Shirai M, Taira K. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5′- and 3′-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev. Nucleic Acids Res. 22:1994;5060-5067.
38. Woisard A, Fourrey JL, Favre A. Multiple folded conformations of a hammerhead ribozyme domain under cleavage conditions. J Mol Biol. 239:1994;366-370.
39. Laugâa P, Woisard A, Fourrey J-L, Favre A. Hammerhead ribozyme: a three dimensional model based on photo-crosslinking data. CR Acad Sci Paris, Sciences de la vie/Life Sci. 318:1995;307-313.
40. Fuerst TR, Niles EG, Studier FW, Moss B. Eucaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Biochemistry. 83:1986;8122-8126.
41. Sambrook J, Fritsch EF, Maniatis T. 2nd edition Molecular cloning: a laboratory manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
42. Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW. Use of T7 polymerase to direct expression of cloned genes. Methods Enzymol. 185:1990;60-89.
43. Graham FL, Van Der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52:1973;456-467.
44. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochem. 162:1987;156-159.
45. Siebert PD, Chenchik A. Modified acid guanidinium thiocyanate-phenol - chloroform RNA extraction method which greatly reduced DNA contamination. Nucleic Acids Res. 21:1993;2019-2020.
46. Fuerst TR, Moss B. Structure and stability of mRNA synthesized by vaccinia virus-encoded bacteriophage T7 RNA polymerase in mammalian cells. Importance of the 5′ untranslated leader. J Mol Biol. 206:1989;333-348.
47. Foley KP, Leonard MW, Engel JD. Quantitation of RNA using the polymerase chain reaction. Trends Genet. 9:1993;380-385.
48. Siebert PD, Kellog DE. McPherson MJ, Hames BD, Taylor GR. 2nd edition PCR2. A practical approach. 1995;135-148 IRL Press, Oxford.
49. Dropulic B, Lin NH, Jeang KT. A method to increase the cumulative cleavage efficiency of ribozymes: thermal cycling. Nucleic Acids Res. 21:1993;2273-2274.
50. Bawdin F, Marquet R, Isel C, Darlix J-L, Ehresmann B, Ehresmann C. Functional sites in the 5′ region of Human Immunodeficiency virus type 1 RNA form defined structural domains. J Mol Biol. 229:1993;382-397.
51. Ventura M, Wang P, Franck N, Saragosti S. Ribozyme targeting of HIV-1 LTR. Biochem Biophys Res Commun. 203:1994;889-898.
52. Crisell P, Thompson S, James W. Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro. Nucleic Acids Res. 21:1993;5251-5255.
53. Tsuchihashi Z, Khosla M, Herschlag D. Protein enhancement of hammerhead ribozyme catalysis. Science. 262:1993;99-102.
54. Heidenreich O, Kang S-H, Brown DA, Swiderski P, Rossi JJ, Eckstein F, Nerenberg M. Ribozyme-mediated RNA degradation in nuclei suspension. Nucleic Acids Res. 23:1995;2223-2228.